Seeking Alpha

QualityStocks'  Instablog

Send Message
QualityStocks ( assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Rafarma Pharmaceuticals, Inc. (RAFA) Sets Sights On High Goals, Takes Aim 0 comments
    Apr 17, 2013 2:04 PM

    Russia-based Rafarma Pharmaceuticals has determined its place in the global pharmaceutical industry and has armed itself with impressive means to get its cards in the stack. The company's initial focus is on Russia's burgeoning domestic pharmaceutical market.

    The Russian pharmaceutical sector is on track to reach a value of $10.7 billion by 2014, $60 billion by 2020 - opportunity is there for the taking. As the Russian Government enforces measures to bolster Russia's domestic pharmaceutical market, Rafarma's aim is to take advantage of government-backed initiatives and emerge as one of the Top 3 Russian pharmaceutical companies within the next decade.

    A goal of this caliber takes some heavy artillery, something much more than a business strategy that looks good on paper. To execute its mission, the company has built a new world-class 270,000 square-foot manufacturing plant hunkered on company-owned land, protecting it from land lock in the event of future expansion.

    Located in Terbuny, Russia, the multi-profile pharmaceutical plant has the capability of producing all types and forms of medical drugs. The facility is supported by the government of Lipetsk region of Russia, Ministry of Health of Russian Federation, and the Ministry of Industry and Trade of Russian Federation, which listed Rafarma as one of the leading and most prospective projects in the modern Russian pharmaceutical and medical industry.

    After investing considerable time and capital into its vast pharmaceutical plant, Rafarma anticipates running at full-throttle by this summer, producing generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products that are approved by the Ministry of Health of Russian Federation.

    For more information, visit

    Please see disclaimer on the QualityStocks website:

Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.